Международный прогностический индекс при распространенных стадиях лимфомы Ходжкина в условиях современной терапии

К. Д. Капланов; А. Л. Шипаева; В. А. Васильева; Э. Г. Гемджян; И. В. Матвеева; Л. С. Трегубова; Т. Ю. Клиточенко; К. В. Демиденко; О. Б. Калашникова; Г. Ю. Выскуб; О. Е. Голубева; О. В. Левина; В. А. Орлов; Е. А. Демина

doi:10.21320/2500-2139-2013-6-3-294-302

International prognostic score in advanced Hodgkin’s lymphoma

K.D. Kaplanov, A.L. Shipaeva, V.A. Vasil’yeva, E.G. Gemdjian, I.V. Matveeva, L.S. Tregubova, T.U. Klitochenko, K.V. Demidenko, O.B. Kalashnikova, G.U. Vyskub, O.E. Golubeva, O.V. Levina, V.A. Orlov, E.A. Demina,

DOI:

https://doi.org/10.21320/2500-2139-2013-6-3-294-302

Abstract Authors References

Since chemotherapy of Hodkgin’s lymphoma was introduced in early 60s, it has undergone fundamental changes that were associated with dramatic improvement in the disease prognosis. Currently, the various intensive modifications of original BEACOPP, such as BEACOPP-14 and escalate BEACOPP, are among the most widely used for treatment of advanced Hodkgin’s lymphoma.

Initially, the International Prognostic Score (IPS) was developed for patients treated with MOPP and MOPP-ABVD protocols. We suggest that due to the well-known changing value of the various prognostic signs with protocols of different intensity, the significance of IPS for BEACOPP-based therapy should be reconsidered.

One hundred seventy two patients with advanced Hodgkin’s lymphoma were included in our trial. All these patients were treated at the Hematology department of Volgograd Regional Oncology Clinic #1. Treatment options were as follows: 64 (37%), 84 (49%), and 24 (14%) patients received intensive BEACOPP-based, standard BEACOPP, or ABVD therapy, respectively. The final data presented are related to the period up to June 30, 2012.

We retrospectively evaluated the treatment outcomes for each IPS group. To distinguish the most significant prognostic signs from all six IPS factors, we studied the impact of each factor on treatment efficacy.

The greatest difference in overall 3- and 4-year survival was observed between the groups of patients with IPS 0–1 and ³ 2; for IPS 0–1, 3- and 4-year overall survival rate was 93%; for IPS ³ 2, 3- and 4-year overall survival rate was 81% and 75%, respectively (p = 0.05). 3-year overall survival was significantly negatively affected by such factors as age over 45 (70% versus 87%, relative risk (RR) = 3.95% CI: 1.7–7, p = 0.01) and albumin level < 40 g/L (79% versus 88%, RR= 2.8, 95% CI: 1.2–6.8, p = 0.02). Overall 3-year survival rate in males (n = 91) and females (n = 81) was 80% and 88%, respectively (p = 0.09). We found no effect on overall and freedom-from-treatment-failure survival (FFTF) of such factors as hemoglobin levels, lymphocyte count, leukocytes count, and IV stage disease. With respect to overall survival, multivariate analysis showed the greatest significance of age (relative risk, RR =3.6, 95% CI: 1.8–7, p = 0.001) and albumin level (OR = 2.6, 95% CI: 1.1–6, p = 0.036).

K.D. Kaplanov Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
A.L. Shipaeva Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
V.A. Vasil’yeva Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
E.G. Gemdjian Hematology Research Center, RF Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический научный центр» МЗ РФ, Москва, Российская Федерация
I.V. Matveeva Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
L.S. Tregubova Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
T.U. Klitochenko Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
K.V. Demidenko Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
O.B. Kalashnikova Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
G.U. Vyskub Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
O.E. Golubeva Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
O.V. Levina Volgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
V.A. Orlov olgograd Regional Oncology Clinic #1, Volgograd, Russian Federation ; ГБУЗ «Волгоградский областной клинический онкологический диспансер № 1», Волгоград, Российская Федерация
E.A. Demina N.N. Blokhin Russian Cancer Research Center, RAMS, Moscow, Russian Federation ; ФГБУ «Российский онкологический центр им Н.Н. Блохина» РАМН, Москва, Российская Федерация

Richardson S.E., McNamara C. The management of classical Hodgkin’s lymphoma: past, present, and future. Advant. Hematol. 2011; 2011: 1–17. DOI: https://doi.org/10.1155/2011/865870
Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematol. Am. Soc. Hematol. Educ. 2009: 497–506. DOI: https://doi.org/10.1182/asheducation-2009.1.497
Federico M., Luminari S., Iannitto E. et al. ABVD compared with BEACOPP compared with CEC for initial treatment of patients with advanced Hodgkin’s lymphoma: Results from the HD2000 Gruppo Italiani perlo Studio dei Linfomi Trial. Clin. Oncol. 2009; 27: 805–11. DOI: https://doi.org/10.1200/JCO.2008.17.0910
Gianni A.M., Rambaldi A., Zinzani P. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma: a randomized trial of the Michelagelo, GITIL and IIL cooperative groups. ASCO meeting Chicago, 2008. Abstract 8506. DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.8506
Byar D.P. Identification of prognostic factors. In: Cancer clinical trials. Methods and practice. Ed. by M.E. Buyse, M.J. Staquet, R.J. Sylvester. Oxford: Oxford University Press, 1988.
Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s disease. N. Engl. J. Med. 1998; 339(21): 1506–14.
R. Optimal Therapy of Advanced Hodgkin Lymphoma. ASH Education book. 2011: 310–316. DOI: https://doi.org/10.1182/asheducation-2011.1.310
Diehl V., Franklin J., Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. Engl. J. Med. 2003; 348(24): 2386–95. DOI: https://doi.org/10.1056/NEJMoa022473
Wagstaff J., Gregory W.M., Swindell R. et al. Prognostic factors for survival in stage IIIB and IV Hodgkin’s disease: a multivariate analyses comparing two specialist treatment centers. J. Cancer. 1988; 58: 487–92. DOI: https://doi.org/10.1038/bjc.1988.246
Wagstaff J., Steward W., Jones M. et al. Factors affecting remission and survival in patients with advanced Hodgkin’s disease treated with MVPP. Oncol. 1986; 4: 135–47. DOI: https://doi.org/10.1002/hon.2900040206
Straus D.J., Gaynor J.J., Myers J. et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. Clin. Oncol. 1990; 8: 1173–86. DOI: https://doi.org/10.1200/JCO.1990.8.7.1173
Proctor S.J., Taylor P., Mackie M.J. et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin’s disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Lymphoma 1992; 7 (Suppl.): 17–20. DOI: https://doi.org/10.3109/10428199209061558
Low S.E., Horsman J.M., Walters S.J. et al. Risk-adjusted prognostic models for Hodgkin’s disease (HD) and grade II non- Hodgkin’s lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients. J. Hematol. 2003; 120: 277–80. DOI: https://doi.org/10.1046/j.1365-2141.2003.04061.x
Gobbi P.G., Comelli M., Grignani G.E. et al. Estimate of expected survival at diagnosis in Hodgkin’s disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin’s Disease (IDHD). Hematologica 1994; 79: 241–55.
Moccia A.A., Donaldson J., Chhanabhai M. et al. International Prognostic Score in Advanced- Stage Hodgkin’s Lymphoma: Altered Utility in the Modern Era. J. Clin. 2012; 30: 3383–8. DOI: https://doi.org/10.1200/JCO.2011.41.0910
Капланов К.Д., Шипаева А.Л., Васильева В.А. и др. Эффективность программ химиотерапии первой линии при различных стадиях лимфомы Ходжкина. Клин. онкогематол. 2012; 1: 22–9. [Kaplanov K.D., Shipayeva A.L., Vasilyeva V.A. i dr. Effektivnost programm khimioterapii pervoy linii pri razlichnykh stadiyakh limfomy Khodzhkina (Efficacy of first-line chemotherapy programs at various stages of Hodgkin’s disease). onkogematol. 2012; 1: 22–9.]

Keywords:

Hodgkin’s lymphoma, international prognostic score (IPS), advanced stages, overall survival (OS), freedom-from-treatment-failure survival (FFTFS), BEACOPP, ABVD

License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

Downloads

PDF_2013-6-3-294-302 (Russian)

Published

01.07.2013

Issue

Vol. 6 No. 3 (2013)

LYMPHOID MALIGNANCIES

How to Cite

Kaplanov K.D., Shipaeva A.L., Vasil’yeva V.A., et al. International prognostic score in advanced Hodgkin’s lymphoma. Clinical Oncohematology. Basic Research and Clinical Practice. 2013;6(3):294–302. doi:10.21320/2500-2139-2013-6-3-294-302.

Download Citation

Most read articles by the same author(s)

V.O. Sarzhevskii, Aisel Akifovna Mamedova, N.E. Mochkin, E.A. Demina, A.A. Spornik, A.A. Samoilova, V.S. Bogatyrev, A.A. Rukavitsyn, E.G. Smirnova, N.S. Shorokhov, A.E. Bannikova, V.Ya. Melnichenko, N.B. Mikhailova, E.S. Borzenkova, L.V. Stelmakh, Yu.R. Zalyalov, A.A. Semenova, G.S. Tumyan, M.A. Danilova, O.A. Konova, N.A. Falaleeva, AYu Terekhova, M.A. Vernyuk, A.M. Chervontseva, L.S. Khairullina, A.A. Maslov, I.B. Lysenko, Yu.A. Alekseeva, E.S. Pavlyuchenko, A.A. Mirsaitov, A.A. Zverkova, I.V. Ishmatova, S.A. Volchenkov, M.S. Motalkina, I.S. Zyuzgin, Nivo-DHAP Combined with Subsequent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Multi-Center Prospective Clinical Trial (ClinicalTrials.gov, NCT04091490) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 17 No. 1 (2024)
Anait Levonovna Melikyan, A.M. Kovrigina, I.N. Subortseva, V.A Shuvaev, E.V. Morozova, E.G. Lomaia, B.V. Afanasyev, T.A. Ageeva, V.V. Baikov, O.Yu. Vinogradova, S.V. Gritsaev, A.Yu. Zaritskey, T.I. Ionova, K.D. Kaplanov, I.S. Martynkevich, T.A. Mitina, E.S. Polushkina, T.I. Pospelova, M.A. Sokolova, A.B. Sudarikov, A.G. Turkina, Yu.V. Shatokhin, R.G. Shmakov, V.G. Savchenko, National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 14 No. 2 (2021)
Evgeniya Viktorovna Paramonova, Yu.I. Klyuchagina, M.Yu. Kichigina, D.N. Tupitsyna, V.O. Shpirko, A.V. Arakelyan, A.A. Semenova, E.A. Demina, O.P. Trofimova, A.S. Subbotin, M.A. Senchenko, G.S. Tumyan, Treatment of Patients with Local Stages of Newly Diagnosed Classical Hodgkin Lymphoma: A Literature Review, Current Approaches, and Our Own Experience , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 17 No. 1 (2024)
A.L. Melikyan, A.G. Turkina, Irina Nikolaevna Subortseva, E.Yu. Chelysheva, A.M. Kovrigina, V.A. Shuvaev, V.V. Baikov, O.Yu. Vinogradova, S.M. Kulikov, A.N. Petrova, A.V. Bykova, A.-P.A. Poshivai, Yu.Yu. Vlasova, M.M. Chukavina, O.D. Serdyuk, K.V. Naumova, N.T. Siordiya, N.S. Lazorko, R.V. Grozov, E.I. Mullo, A.S. Maksimova, O.M. Senderova, O.V. Kanya, M.S. Fominykh, D.I. Shikhbabaeva, E.A. Belyakova, I.S. Martynkevich, L.B. Polushkina, M.N. Zenina, E.V. Efremova, V.I. Rugal, L.P. Papayan, N.E. Korsakova, O.Yu. Matvienko, E.B. Syrtseva, S.V. Gappoev, M.V. Barabanshchikova, M.O. Ivanova, K.D. Kaplanov, E.S. Rogova, K.B. Trizna, A.S. Zhevnyak, O.E. Ochirova, A.A. Shakhaeva, A.S. Lyamkina, I.P. Mikhno, Yu.B. Chernykh, T.V. Chudanova, I.N. Kontievskii, N.N. Glonina, M.V. Burundukova, Materials of the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” (March 15–16, 2019; National Research Center for Hematology, Moscow) , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 13 No. 2 (2020)
T.I. Ionova, A.A. Amdiev, M.I. Andrievskikh, E.A. Baryakh, E.V. Vasilev, M.V. Volkov, E.M. Volodicheva, V.V. Ivanov, O.V. Kaverina, K.D. Kaplanov, T.Yu. Klitochenko, V.I. Kurakin, D.G. Lazareva, O.G. Larionova, K.V. Lepik, I.B. Lysenko, V.Ya. Melnichenko, R.I. Minullina, O.V. Mironov, E.N. Misyurina, N.B. Mikhailova, N.E. Mochkin, Tatyana Pavlovna Nikitina, T.S. Petrova, N.M. Porfireva, O.A. Rukavitsyn, A.A. Samoilova, R.N. Safin, P.I. Simashova, E.G. Smirnova, N.A. Trenina, N.V. Fadeeva, G.N. Khusainova, V.L. Chang, T.V. Shelekhova, D.G. Sherstnev, The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 15 No. 1 (2022)
T.I. Ionova, E.A. Andreevskaya, E.N. Babich, N.B. Bulieva, O.Yu. Vinogradova, E.M. Volodicheva, S.V. Voloshin, N.N. Glonina, S.K. Dubov, N.B. Esef’eva, A.Yu. Zaritskey, E.E. Zinina, M.O. Ivanova, T.Yu. Klitochenko, A.V. Kopylova, A.D. Kulagin, G.B. Kuchma, O.Yu. Li, E.G. Lomaia, A.L. Melikyan, V.Ya. Melnichenko, S.N. Menshakova, N.V. Minaeva, T.A. Mitina, E.V. Morozova, Tatyana Pavlovna Nikitina, O.E. Ochirova, A.S. Polyakov, T.I. Pospelova, A.V. Proidakov, O.A. Rukavitsyn, G.Sh. Safuanova, I.N. Subortseva, M.S. Fominykh, M.V. Frolova, T.V. Shelekhova, D.G. Sherstnev, T.V. Shneider, V.A. Shuvaev, Z.K. Abdulkhalikova, L.V. Anchukova, I.A. Apanaskevich, A.N. Arnautova, M.V. Barabanshchikova, N.V. Berlina, A.P. Bityukov, E.A. Gilyazitdinova, V.I. Gilmanshina, E.K. Egorova, E.V. Efremova, E.B. Zhalsanova, E.N. Kabanova, O.B. Kalashnikova, A.E. Kersilova, T.I. Kolosheinova, P.M. Kondratovskii, E.V. Koroleva, A.N. Kotelnikova, N.A. Lazareva, N.S. Lazorko, E.V. Lyyurova, A.S. Lyamkina, Yu.N. Maslova, E.S. Mileeva, N.E. Mochkin, E.K. Nekhai, Ya.A. Noskov, E.S. Osipova, M.M. Pankrashkina, E.V. Potanina, O.D. Rudenko, T.Yu. Rozhenkova, E.I. Sbityakova, N.T. Siordiya, A.V. Talko, E.I. Usacheva, Yu.B. Chernykh, T.V. Chitanava, K.S. Shashkina, D.I. Shikhbabaeva, K.S. Yurovskaya, Current Quality-of-Life Aspects in Patients with Classical Ph-Negative Myeloproliferative Neoplasms in the Russian Federation: Results and Discussion of the National Observational Program MPN-QoL-2020 , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 15 No. 2 (2022)
Anna Anatolevna Spornik, N.S. Vasilev, A.A. Samoilova, A.A. Mamedova, V.S. Bogatyrev, E.G. Smirnova, A.A. Bannikova, A.A. Rukavitsyn, N.S. Shorokhov, N.E. Mochkin, V.O. Sarzhevskii, E.A. Demina, V.Ya. Melnichenko, Primary Prevention of Neutropenia by Empegfilgrastim in Patients with Advanced Stages of Classical Hodgkin Lymphoma Treated with Intensive First-Line Chemotherapy with a Modified 6-Cycle Program EACODD-14 Under the Protocol “LKh-Rossiya-1” , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 16 No. 4 (2023)
Ivan Sergeevich Moiseev, S.M. Alekseev, N.B. Mikhailova, K.D. Kaplanov, M.V. Demchenkova, L.V. Anchukova, V.V. Baikov, A.M. Belyaev, Yu.A. Vasil’eva, N.P. Volkov, Yu.N. Vinogradova, A.Yu. Zaritskey, A.E. Zdorov, N.V. Il’in, L.O. Kashintseva, E.V. Kondakova, P.V. Kotselyabina, V.A. Lapin, K.V. Lepik, I.V. Lesechko, V.M. Moiseenko, G.M. Manikhas, N.V. Medvedeva, Yu.A. Oleinik, E.S. Pavlyuchenko, K.S. Parfenova, E.V. Patrakova, A.V. Proidakov, D.V. Saidullaeva, E.V. Tarasova, A.L. Shipaeva, T.V. Shneider, B.V. Afanasyev, Results of the Russian Multi-Center Cooperative Prospective-Retrospective Observational Program for Hodgkin’s Lymphoma Treatment RNWOHG-HD1 , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 14 No. 4 (2021)
Sergei Nikolaevich Bondarenko, E.N. Parovichnikova, A.A. Maschan, O.Yu. Baranova, T.V. Shelekhova, V.A. Doronin, V.Ya. Mel’nichenko, K.D. Kaplanov, O.S. Uspenskaya, A.N. Sokolov, N.V. Myakova, I.S. Moiseev, I.V. Markova, E.I. Darskaya, A.G. Smirnova, T.A. Bykova, B.I. Ayubova, I.A. Samorodova, E.V. Babenko, I.M. Barkhatov, T.L. Gindina, A.D. Kulagin, B.V. Afanas’ev, Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 12 No. 2 (2019)
N.V. Zhukov, A.G. Rumyantsev, A.L. Uss, N.F. Milanovich, V.V. Ptushkin, B.V. Afanasyev, N.B. Mikhaylova, V.B. Larionova, E.A. Demina, E.E. Karamanesht, N.G. Tyurina, M.A. Vernyuk, A.D. Kaprin, High-Dose Chemotherapy and Autologous Stem Cells Transplantation for Relapsed/Refractory Hodgkin’s Lymphoma. Is There an Equal Right to Life? , Clinical Oncohematology. Basic Research and Clinical Practice: Vol. 7 No. 3 (2014)